Background
Brian Rifkin
Attacking the Origin of IgAN: ORIGIN3 and ...

This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.

Attacking the Origin of IgAN: ORIGIN3 and Atacicept
news
swapnil hiremath
Kidney Week in Houston: Day 3

Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.

Kidney Week in Houston: Day 3
Background, news
swapnil hiremath
Kidney Week in Houston: Day 2

in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more

Kidney Week in Houston: Day 2
Background, news
swapnil hiremath
Kidney Week in Houston: Day 1

in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis

Kidney Week in Houston: Day 1
Background
Cristina Adriana Popa
2025 IgAN KDIGO guidelines: fresh out of ...

This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy

2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully

hypernatremia

Hypernatremia Speed of Correction Tweetorial

This was NephJC’s first Tweetorial. We hope to make these regular components of the content NephJC generates to describe and disseminate the latest research.